Intractable recurrent hepatitis A virus infection requiring repeated liver transplantation: A case report

G. C. Park, S. Hwang, Young-Dong Yu, P. J. Park, Y. I. Choi, G. W. Song, D. H. Jung, C. S. Ahn, K. H. Kim, D. B. Moon, T. Y. Ha, S. G. Lee

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Although hepatitis A virus (HAV) infection is usually self-limited, it may induce fulminant hepatitis. We present an unusual case of a 40-year-old, otherwise healthy man with intractable recurrent HAV infection requiring retransplantation after primary liver transplantation for HAV-associated fulminant liver failure. After the first living-donor liver transplantation, allograft function recovered uneventfully; however, beginning at 35 days, his serum total bilirubin concentration increased, reaching 40 mg/dL, with a slight increase in liver enzymes. Detection of genomic HAV RNA in serum at the time of graft dysfunction led to a diagnosis of recurrent HAV infection. Fifty-one days after the first transplant, he underwent a deceased donor retransplantation. His allograft function recovered; the patient was discharged from the hospital. Sixty-five days later, however, he was readmitted for colitis-like symptoms and was again treated for acute rejection, but died owing to overwhelming sepsis and persistence of HAV infection. These findings indicate that patients who undergo liver transplantation for HAV-associated liver disease may be at risk of HAV reinfection, particularly if they require anti-rejection therapy. Routine measurements of anti-HAV immunoglobulin M and HAV RNA during the early posttransplant period in HAV-associated liver transplant recipients may differentiate reinfection from an acute cellular rejection episode.

Original languageEnglish
Pages (from-to)4658-4660
Number of pages3
JournalTransplantation Proceedings
Volume42
Issue number10
DOIs
Publication statusPublished - 2010 Dec 1
Externally publishedYes

Fingerprint

Hepatitis A virus
Virus Diseases
Liver Transplantation
Allografts
RNA
Transplants
Acute Liver Failure
Living Donors
Liver
Colitis
Serum
Bilirubin
Immunosuppression
Hepatitis
Immunoglobulin M
Liver Diseases
Sepsis
Tissue Donors

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Intractable recurrent hepatitis A virus infection requiring repeated liver transplantation : A case report. / Park, G. C.; Hwang, S.; Yu, Young-Dong; Park, P. J.; Choi, Y. I.; Song, G. W.; Jung, D. H.; Ahn, C. S.; Kim, K. H.; Moon, D. B.; Ha, T. Y.; Lee, S. G.

In: Transplantation Proceedings, Vol. 42, No. 10, 01.12.2010, p. 4658-4660.

Research output: Contribution to journalArticle

Park, GC, Hwang, S, Yu, Y-D, Park, PJ, Choi, YI, Song, GW, Jung, DH, Ahn, CS, Kim, KH, Moon, DB, Ha, TY & Lee, SG 2010, 'Intractable recurrent hepatitis A virus infection requiring repeated liver transplantation: A case report', Transplantation Proceedings, vol. 42, no. 10, pp. 4658-4660. https://doi.org/10.1016/j.transproceed.2010.09.151
Park, G. C. ; Hwang, S. ; Yu, Young-Dong ; Park, P. J. ; Choi, Y. I. ; Song, G. W. ; Jung, D. H. ; Ahn, C. S. ; Kim, K. H. ; Moon, D. B. ; Ha, T. Y. ; Lee, S. G. / Intractable recurrent hepatitis A virus infection requiring repeated liver transplantation : A case report. In: Transplantation Proceedings. 2010 ; Vol. 42, No. 10. pp. 4658-4660.
@article{509f9ec05ba14e86bfb44bd5bcaac0d2,
title = "Intractable recurrent hepatitis A virus infection requiring repeated liver transplantation: A case report",
abstract = "Although hepatitis A virus (HAV) infection is usually self-limited, it may induce fulminant hepatitis. We present an unusual case of a 40-year-old, otherwise healthy man with intractable recurrent HAV infection requiring retransplantation after primary liver transplantation for HAV-associated fulminant liver failure. After the first living-donor liver transplantation, allograft function recovered uneventfully; however, beginning at 35 days, his serum total bilirubin concentration increased, reaching 40 mg/dL, with a slight increase in liver enzymes. Detection of genomic HAV RNA in serum at the time of graft dysfunction led to a diagnosis of recurrent HAV infection. Fifty-one days after the first transplant, he underwent a deceased donor retransplantation. His allograft function recovered; the patient was discharged from the hospital. Sixty-five days later, however, he was readmitted for colitis-like symptoms and was again treated for acute rejection, but died owing to overwhelming sepsis and persistence of HAV infection. These findings indicate that patients who undergo liver transplantation for HAV-associated liver disease may be at risk of HAV reinfection, particularly if they require anti-rejection therapy. Routine measurements of anti-HAV immunoglobulin M and HAV RNA during the early posttransplant period in HAV-associated liver transplant recipients may differentiate reinfection from an acute cellular rejection episode.",
author = "Park, {G. C.} and S. Hwang and Young-Dong Yu and Park, {P. J.} and Choi, {Y. I.} and Song, {G. W.} and Jung, {D. H.} and Ahn, {C. S.} and Kim, {K. H.} and Moon, {D. B.} and Ha, {T. Y.} and Lee, {S. G.}",
year = "2010",
month = "12",
day = "1",
doi = "10.1016/j.transproceed.2010.09.151",
language = "English",
volume = "42",
pages = "4658--4660",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "10",

}

TY - JOUR

T1 - Intractable recurrent hepatitis A virus infection requiring repeated liver transplantation

T2 - A case report

AU - Park, G. C.

AU - Hwang, S.

AU - Yu, Young-Dong

AU - Park, P. J.

AU - Choi, Y. I.

AU - Song, G. W.

AU - Jung, D. H.

AU - Ahn, C. S.

AU - Kim, K. H.

AU - Moon, D. B.

AU - Ha, T. Y.

AU - Lee, S. G.

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Although hepatitis A virus (HAV) infection is usually self-limited, it may induce fulminant hepatitis. We present an unusual case of a 40-year-old, otherwise healthy man with intractable recurrent HAV infection requiring retransplantation after primary liver transplantation for HAV-associated fulminant liver failure. After the first living-donor liver transplantation, allograft function recovered uneventfully; however, beginning at 35 days, his serum total bilirubin concentration increased, reaching 40 mg/dL, with a slight increase in liver enzymes. Detection of genomic HAV RNA in serum at the time of graft dysfunction led to a diagnosis of recurrent HAV infection. Fifty-one days after the first transplant, he underwent a deceased donor retransplantation. His allograft function recovered; the patient was discharged from the hospital. Sixty-five days later, however, he was readmitted for colitis-like symptoms and was again treated for acute rejection, but died owing to overwhelming sepsis and persistence of HAV infection. These findings indicate that patients who undergo liver transplantation for HAV-associated liver disease may be at risk of HAV reinfection, particularly if they require anti-rejection therapy. Routine measurements of anti-HAV immunoglobulin M and HAV RNA during the early posttransplant period in HAV-associated liver transplant recipients may differentiate reinfection from an acute cellular rejection episode.

AB - Although hepatitis A virus (HAV) infection is usually self-limited, it may induce fulminant hepatitis. We present an unusual case of a 40-year-old, otherwise healthy man with intractable recurrent HAV infection requiring retransplantation after primary liver transplantation for HAV-associated fulminant liver failure. After the first living-donor liver transplantation, allograft function recovered uneventfully; however, beginning at 35 days, his serum total bilirubin concentration increased, reaching 40 mg/dL, with a slight increase in liver enzymes. Detection of genomic HAV RNA in serum at the time of graft dysfunction led to a diagnosis of recurrent HAV infection. Fifty-one days after the first transplant, he underwent a deceased donor retransplantation. His allograft function recovered; the patient was discharged from the hospital. Sixty-five days later, however, he was readmitted for colitis-like symptoms and was again treated for acute rejection, but died owing to overwhelming sepsis and persistence of HAV infection. These findings indicate that patients who undergo liver transplantation for HAV-associated liver disease may be at risk of HAV reinfection, particularly if they require anti-rejection therapy. Routine measurements of anti-HAV immunoglobulin M and HAV RNA during the early posttransplant period in HAV-associated liver transplant recipients may differentiate reinfection from an acute cellular rejection episode.

UR - http://www.scopus.com/inward/record.url?scp=78650494399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650494399&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2010.09.151

DO - 10.1016/j.transproceed.2010.09.151

M3 - Article

C2 - 21168755

AN - SCOPUS:78650494399

VL - 42

SP - 4658

EP - 4660

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 10

ER -